Sage turns focus for key drug to treatment-resistant depression - BioPharma Dive

Sage turns focus for key drug to treatment-resistant depression  BioPharma DiveSage Therapeutics has ambition to match its lofty $9 billion market valuation. Developer of the first drug ever approved in the U.S. for postpartum depression, ...